Table 1.
Characteristics of included studies.
| Authors& Publiation year |
Registration number | Intervention model | Study phase | Type of publication | Group | Modality of neoadjuvant therapy | Chemotherapy regimen | Radiotherapy regimen | Main inclusion criteria | ICI | Dose of ICI | Cycles of ICI |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cower, D., et al. (19), 2022 | NCT02962063 | single-arm | II | abstract | NICRT | induced chemotherapy plus concurrent NICRT | induced mFOLFOX; concurrent 5-FU/CAP+OX or paclitaxel/carboplatin | 50.4Gy | resectable cTxN+ or T3-4Nx, M0 esophageal/GEJ adenocarcinoma | durvalumab | 1500mg iv Q4w | 2 |
| Jiang, N., et al. (23), 2022 | ChiCTR2100045104 | single-arm | II | abstract | NICRT | concurrent NICRT | paclitaxel, carboplatin | 30Gy/12f | resectable cT3-4aN0 or cT1-4aN+, M0 ESCC | toripalimab | 240mg iv Q3w | 2 |
| Kelly, R. J., et al. (32), 2022 | NCT03044613 | dual-arm | II | abstract | NICRT | cohort A & original cohort B: induced immunotherapy plus concurrent NICRT; amended cohort B: induced immunotherapy plus concurrent CRT | paclitaxel, carboplatin | 41.1Gy/23f | stage II-III esophageal/GEJ cancer | cohort A: nivolumab; cohort B: nivolumab+relatlimab |
cohort A: 240mg Q2w; cohort B: 240mg Q2w(nivolumab)+80mg Q2w(relatlimab) | cohort A & original cohort B:5; amended cohort B: 2 |
| Lee, S., et al. (33), 2019 | NCT02844075 | single-arm | II | abstract | NICRT | concurrent NICRT | paclitaxel, carboplatin | 44.1Gy/21f | stage IB-III ESCC | pembrolizumab | 200 mg iv Q3w | 2 |
| Li, C., et al. (12), 2021 | NCT03792347 | single-arm | IB | article | NICRT | concurrent NICRT | paclitaxel, carboplatin | 41.4Gy/23f | resectable cT2-T4aNxM0 ESCC | pembrolizumab | 2 mg/kg iv Q3w | 2 |
| Manish A. Shah, et al. (39), 2021 | NCT02998268 | dual-arm | II | abstract | NICRT | cohort A: induced chemotherapy plus concurrent NICRT; cohort B: induced immuno-chemotherapy plus concurrent NICRT | paclitaxel, carboplatin | 41.4Gy/23f | resectable cT3-4Nx or T2N1, M0 esophageal/GEJ adenocarcinoma | pembrolizumab | 200 mg iv Q3w | NA |
| Uboha, NV., et al. (25), 2022 | NCT03490292 | Single-arm | I/II | abstract | NICRT | concurrent NICRT | paclitaxel, carboplatin | 41.4Gy/23f | potentially curable cT1N1 or cT2-3N0-2, M0 esophageal/GEJ SCC/AC | avelumab | 10mg/kg iv Q2w | 3 |
| Qi, W.X., et al. (41), 2020 | NA | single-arm | IB | abstract | NICRT | concurrent NICRT | paclitaxel, carboplatin | 41.4Gy/23f | local advanced resectable ESCC | pembrolizumab | 2 mg/kg iv Q3w | 2 |
| van Den Ende, T., et al. (13), 2021 | NCT03087864 | single-arm | II | article | NICRT | concurrent NICRT | paclitaxel, carboplatin | 41.4Gy/23f | resectable <T4b, NxM0 esophageal/GEJ adenocarcinoma | atezolizumab | 1200 mg iv Q3w | 2 |
| Xu, X., et al. (28), 2022 | NCT04437212 | single-arm | II | abstract | NICRT | concurrent NICRT | paclitaxel, cisplatin | 41.4Gy/23f | resectable cT1-4aN1-2 or T3-4aN0,MO ESCC | toripalimab | 240mg iv Q3w | 2 |
| Duan, H., et al. (29), 2021 | NA | single-arm | NA | article | NICT | concurrent NICT | docetaxel, paclitaxel nedaplatin | resectable cT2-xNxM0 ESCC | sintilimab | 200 mg iv Q3w | 3 | |
| Gao, L., et al. (20), 2022 | ChiCTR2100052784 | single-arm | II | article | NICT | concurrent NICT | docetaxel, cisplatin | resectable cT3-4Nx or cTxN+, M0 ESCC | toripalimab | 240 mg iv Q3w | 2 | |
| Gu, Y., et al. (30), 2020 | NCT03946969 | single-arm | IB/II | abstract | NICT | concurrent NICT | paclitaxel, carboplatin, S1 | resectable cT1b-T3NxM0 ESCC | sintilimab | 200 mg iv Q3w | 2 | |
| Guo, J., et al. (21), 2022 | ChiCTR2000040345 | single-arm | II | abstract | NICT | concurrent NICT | paclitaxel, nedaplatin | resectable cT2-4N1-3M0 ESCC | sintilimab | 200mg iv Q3w | 2 | |
| He, W., et al. (31), 2022 | NCT04177797 | single-arm | II | article | NICT | concurrent NICT | paclitaxel, carboplatin | resectable cT3N1-3M0 ESCC | toripalimab | 240 mg iv Q3w | 2 | |
| Jiang, B., et al. (22), 2022 | NA | single-arm | II | abstract | NICT | concurrent NICT | paclitaxel, cisplatin | resectable stage III ESCC | camrelizumab/sintilimab/tislelizumab | 200mg iv Q3w | 2 | |
| Li, K., et al. (34), 2020 | ChiCTR2000035237 | single-arm | pilot study | abstract | NICT | concurrent NICT | paclitaxel, carboplatin | resectable cT2-T4N0-N2M0 ESCC | toripalimab | 240 mg iv Q3w | 2~3 | |
| Li, Z., et al. (24), 2022 | NA | single-arm | II | abstract | NICT | concurrent NICT | paclitaxel, cisplatin | locally advanced ESCC | sintilimab | 200mg iv Q3w | 2~4 | |
| Liu, D., et al. (35), 2021 | ChiCTR1900025318 | single-arm | II | abstract | NICT | concurrent NICT | paclitaxel, cisplatin | resectable cT1-cT2N+ or cT3-cT4aNx ESCC | toripalimab | 240 mg iv Q3w | 2 | |
| Liu, J.; Li, J., et al. (36), 2022 | NCT04225364 | single-arm | II | article | NICT | concurrent NICT | paclitaxel, cisplatin | resectable stage II-IVA ESCC | camrelizumab | 200 mg iv Q3w | 2 | |
| Liu, J.; Yang, Y., et al. (37), 2022 | ChiCTR1900026240 | single-arm | II | article | NICT | concurrent NICT | paclitaxel, carboplatin | resectable ESCC, staged as T1b-4a, N2-3 (≥ 3 stations), M0 or M1 lymph node metastasis (confined to the supraclavicular lymph nodes) | camrelizumab | 200 mg iv Q3w | 2 | |
| Ma, J., et al. (38), 2021 | ChiCTR2000033761 | single-arm | II | abstract | NICT | concurrent NICT | paclitaxel, nedaplatin | resectable IIA-IIIB ESCC | camrelizumab | 200 mg iv Q3w | 2~4 | |
| Shang, X., et al. (42), 2021 | NCT 04389177 | single-arm | II | abstract | NICT | concurrent NICT | paclitaxel, cisplatin | potentially resectable cT3N1 or cT1-3N2, M0 ESCC | pembrolizumab | 200 mg iv Q3w | 3 | |
| Shen, D., et al. (43), 2021 | NA | single-arm | pilot study | article | NICT | concurrent NICT | paclitaxel, carboplatin | potentially curable cT1N1-3 or cT2-4aNx, M0 ESCC | nivolumab/pembrolizumab/camrelizumab | nivolumab 3mg/kg iv Q3w, pembrolizumab 2mg/kg iv Q3w, camrelizumab 200mg iv Q3w | 2 | |
| Wang, F., et al. (55), 2021 | NCT03917966 | single-arm | II | abstract | NICT | induced immunotherapy plus concurrent NICT | docetaxel, nedaplatin | stage II-IVA ESCC | camrelizumab | 200 mg iv Q3w | 1+2 | |
| Wang, W., et al. (26), 2022 | NA | single-arm | II | abstract | NICT | concurrent NICT | docetaxel, cisplatin/carboplatin | resectable stage IIB-IVA ESCC | pembrolizumab | 200mg iv Q3w | 4 | |
| Wang, Z., et al. (44), 2021 | ChiCTR1900023880 | single-arm | IB | abstract | NICT | concurrent NICT | paclitaxel, nedaplatin, apatinib | resectable cT1N2 or T2-3N0-2 ESCC | camrelizumab | 200 mg iv Q2w | 2~4 | |
| Xing, W., et al. (45), 2021 | NCT03985670 | dual-arm | II | article | NICT | concurrent NICT | paclitaxel, cisplatin | resectable stage II-IVA ESCC | toripalimab | 240 mg iv Q3w | 2 | |
| Xu, W., et al. (56), 2022 | NCT04506138 | single-arm | II | abstract | NICT | concurrent NICT | paclitaxel, carboplatin | resectable cT2-4aNx or cT1-3N+, M0 ESCC | camrelizumab | 200 mg iv Q3w | 2 | |
| Yamamoto, S.; Matsuda, S., et al. (40, 46), 2021&2022 | NCT03914443 | multi-arm | I | abstract | NICT | cohort A&C: concurrent NICT; cohort B&D: induced immunotherapy plus concurrent NICT | cohort A&B: cisplatin, 5-FU; cohort C&D: cisplatin, 5-FU, docetaxel | resectable cT1N1-3 or cT2-3Nx, M0 ESCC | nivolumab | cohort A&C: 360mg iv Q3w; cohort B&D: 240 mg lead-in followed by 360 mg iv Q3w | cohort A: 2; cohrot B&C: 3; cohort D: 4 | |
| Yan, X., et al. (47), 2021 | ChiCTR2000037488 | single-arm | II | abstract | NICT | concurrent NICT | paclitaxel, carboplatin | resectable stage II-IVA ESCC | tislelizumab | 200 mg iv Q3w | 3 | |
| Yang, P., et al. (48), 2021 | ChiCTR2100051903 | single-arm | pilot study | article | NICT | concurrent NICT | paclitaxel, carboplatin | potentially curable cT1N1-3 or cT2-4aNx, M0 ESCC | camrelizumab | 200 mg iv Q3w | 2 | |
| Yang, W., et al. (49), 2021 | ChiCTR2000028900 | single-arm | pilot study | article | NICT | concurrent NICT | paclitaxel, carboplatin | resectable stage II-III ESCC | camrelizumab | 200 mg iv Q3w | 2 | |
| Zhang, G., et al. (50), 2020 | ChiCTR1900027160 | NA | observational study | abstract | NICT | concurrent NICT | paclitaxel, S1 | resectable stage I-III ESCC | toripalimab | NA | 2~4 | |
| Zhang, X (51)., 2021 | ChiCTR2000029807 | single-arm | II | abstract | NICT | concurrent NICT | paclitaxel, S1 | resectable stage II-III thoracic ESCC | camrelizumab | 200mg iv Q3w | 3 | |
| Zhang, Y., et al. (52), 2022 | ChiCTR2000039170 | NA | Observational study | abstract | NICT | NA | primarily paclitaxel and nedaplatin | resectable EC | camrelizumab | NA | NA | |
| Zhang, Z.; Hong, Z., et al. (53), 2021 | ChiCTR2100045659 | single-arm | II | article | NICT | concurrent NICT | paclitaxel, cisplatin | cT3-4aN0-3 or cT1-2N1-3, M0 ESCC | sintilimab | 200 mg iv Q3w | 2 | |
| Zhang, Z.; Ye, J., et al. (54), 2021 | ChiCTR1900026593 | single-arm | II | abstract | NICT | concurrent NICT | paclitaxel, carboplatin | resectable stage II-IVA ESCC | sintilimab | 200 mg iv Q3w | 2 |
ICI, immune checkpoint inhibitors; NICRT, neoadjuvant immune-chemoradiotherapy; NICT, neoadjuvant immune-chemotherapy; GEJ, gastroesophageal junction; EC, esophageal cancer; ESCC, esophageal squamous cell carcinoma; NA, not available; CAP, capecitabine; OX, oxaliplatin.